论文部分内容阅读
青少年偏头痛的发病率在4％以上。Sumatriptan是治疗偏头痛的一种新药,该药的疗效在成人中已证实,但应用于青少年则很少。作者选择17例青少年偏头痛急性发作期患者,男7例,女10例,年龄6～16岁。其中15例无先兆症状,2例有先兆症状。病史1～12年;平均3.7年。所有患者均排除了心脏病,均未用过麦角胺制剂,均于急性发作1小时内进行皮下注射Sumatriptan。17例患者有15例给予Sumatriptan 6mg,2例给予3mg。将症状分为0～10级,于注射后2小时内评价疗效。结果发现Sumatriptan注射后1小时内头痛消失6例,头痛缓解5例。4例女性混合性偏头痛患者治疗无效。另2例年
The incidence of migraine in adolescents is above 4%. Sumatriptan is a new drug for the treatment of migraine. The efficacy of this medicine has been confirmed in adults, but it is rarely used in adolescents. The authors selected 17 cases of acute migraine migraine patients, 7 males and 10 females, aged 6 to 16 years. Among them, 15 cases had no aura symptoms and 2 cases had aura symptoms. A history of 1 to 12 years; an average of 3.7 years. All patients were excluded from heart disease and none of the ergotamine formulations were used. Sumatriptan was injected subcutaneously within 1 hour of the onset of the acute episode. Seventeen patients had Sumatriptan 6 mg in 15 patients and 3 mg in 2 patients. The symptoms were divided into 0 to 10 levels, within 2 hours after injection evaluation of efficacy. The results showed that within 1 hour after Sumatriptan injection headache disappeared in 6 cases, headache relief in 5 cases. Four women with mixed migraine were ineffective. Another 2 cases of years